Rodolphe Clerval

Rodolphe Clerval

Company: Coave Therapeutics

Job title: Chief Executive Officer


Rodolphe has over 20 years’ experience in the pharma and biotech industry. Rodolphe joined Coave Therapeutics in 2020 from Enterome, which he co-founded. Rodolphe has previously worked in business development at TcLand Expression and Genzyme, and as a sell-side equity analyst at Natixis Bank. Rodolphe graduated with a M.Sc. degree in Biochemical Engineering from Polytech Marseille and is a Certified European Financial Analyst from EFFAS-SFAF.


Highlighting Better Tissue-Specificity Development Efforts for IV-Administered Vectors 11:00 am

Improving capsid and payload design efforts to increase tissue specificity Decreasing vector sequestration by the liver: does liver de-targeting impact extrahepatic biodistribution? Highlighting detargeting efforts of other off-target tissues (e.g. DRG detargeting for CNS targeted capsids)Read more

day: Conference Day One

Delve into the Latest Understanding of Capsid Structure-Function Relationships to Generate Tissue-Specific and Immune-Evading Capsids 3:01 pm

Read more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.